Citations

Clear

6273 citation(s) found for "To, Andrew".

Microbiologic Diagnosis of Prosthetic Shoulder Infection by Use of Implant Sonication
Piper, Kerryl E., Jacobson, Melissa, Cofield, Robert H. , Sperling, John W. , Osmon, Douglas R. , McDowell, Andrew , Patrick, Sheila , Steckelberg, James M., Mandrekar, Jayawant N. , Sampedro, Marta Fernández , Patel, Robin , Sánchez‐Sotelo, Joaquín , Patel, Robin

Mayo Clinic

Journal of Clinical Microbiology | March 5, 2009 | Volume: 47 | Issue: 6 | Pages: 1878-1884

10.1128/jcm.01686-08 | PMID 19261785 Get It

ABSTRACT We recently described a sonication technique for the diagnosis of prosthetic knee and hip infections. We compared periprosthetic tissue culture to implant sonication followed by sonicate fluid culture for the diagnosis of prosthetic shoulder infection. One hundred thirty-six patients undergoing arthroplasty revision or resection were studied; 33 had definite prosthetic shoulder infections and 2 had probable prosthetic shoulder infections. Sonicate fluid culture was more sensitive than periprosthetic tissue culture for the detection of definite prosthetic shoulder infection (66.7 and 54.5%, respectively; P = 0.046). The specificities were similar (98.0% and 95.1%, respectively; P = 0.26). Propionibacterium acnes was the commonest species detected among culture-positive definite prosthetic shoulder infection cases by periprosthetic tissue culture (38.9%) and sonicate fluid culture (40.9%). All subjects from whom P. acnes was isolated from sonicate fluid were male. We conclude that sonicate fluid culture is useful for the diagnosis of prosthetic shoulder infection.
Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Inwards, David J. , Spies, Stewart, Wiseman, Gregory A., Patton, David R. , Erwin, William D. , Rademaker, Alfred , Weitner, Bing Bing, Williams, Stephanie , Tallman, Martin S. , Micallef, Ivana N. , Mehta, Jayesh, Evens, Andrew M. , Zimmer, Michael, Molina, Arturo , Gordon, Leo I. , Winter, Jane N. , Singhal, Seema , White, Christine A. , Gordon, Leo I , Evens, Andrew M , Patton, David R

Mayo Clinic

Journal of Clinical Oncology | March 3, 2009 | Volume: 27 | Issue: 10 | Pages: 1653-1659

10.1200/jco.2008.19.2245 | PMID 19255322 Get It

Purpose To determine the maximum-tolerated radiation-absorbed dose (RAD) to critical organs delivered by yttrium-90 (90Y) ibritumomab tiuxetan in combination with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy with autologous transplantation. Patients and Methods Eligible patients had relapsed or refractory CD20+ non-Hodgkin's lymphoma (NHL). Individualized 90Y activities were based on dosimetry and were calculated to deliver cohort-defined RAD (1 to 17 Gy) to critical organs with three to six patients per cohort. The therapeutic dose of 90Y ibritumomab tiuxetan was followed by high-dose BEAM and autologous transplantation. Results Forty-four patients were treated. Thirty percent of patients had achieved less than a partial remission to their most recent therapy and would not have been eligible for autologous transplantation at most centers. The toxicity profile was similar to that associated with high-dose BEAM chemotherapy. Two dose-limiting toxicities occurred at the 17 Gy dose level, which made 15 Gy the recommended maximum-tolerated RAD. Although eight patients received at least twice the conventional dose of 0.4 mCi/kg, a weight-based strategy at 0.8 mCi/kg would have resulted in a wide range of RAD; nearly 25% of patient cases would have received 17 Gy or more, and many would have received less than 10 Gy. With a median follow-up of 33 months for all patients, the estimated 3-year progression-free and overall survivals were 43% and 60%, respectively. Conclusion Dose-escalated 90Y ibritumomab tiuxetan may be safely combined with high-dose BEAM with autologous transplantation and has the potential to be more effective than standard-dose radioimmunotherapy. Careful dosimetry is required to avoid toxicity and undertreatment.
AQP4-IgG Immunoprecipitation Assay Optimization
Apiwattanakul, Metha , McKeon, Andrew , Fryer, James P., Hinson, Shannon R., Pittock, Sean J. , Lennon, Vanda A. , Pittock, S J , McKeon, Andrew

Mayo Clinic

Clinical Chemistry | February 25, 2009 | Volume: 55 | Issue: 3 | Pages: 592-594

10.1373/clinchem.2008.116848 | PMID 19246407 Get It

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Tr
Rowe, Jacob M. , Richards, Susan , Buck, Georgina , Moorman, Anthony V. , Durrant, Ian, Marks, David I. , McMillan, Andrew , Litzow, Mark R. , Foroni, Letizia, Dewald, Gordon W., Franklin, Ian M., Luger, Selina M. , Paietta, Elisabeth , Wiernik, Peter H. , Tallman, Martin S. , Goldstone, Anthony H., Fielding, Adele K. , Lazarus, Hillard M. , Franklin, Ian M.

Mayo Clinic

Blood | February 25, 2009 | Volume: 113 | Issue: 19 | Pages: 4489-4496

10.1182/blood-2009-01-199380 | PMID 19244158 Get It

Abstract Prospective data on the value of allogeneic hematopoietic stem cell transplantation (alloHSCT) in Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) are limited. The UKALLXII/ECOG 2993 study evaluated the outcome of assigning alloHSCT with a sibling (sib) or matched unrelated donor (MUD) to patients younger than 55 years of age achieving complete remission (CR). The CR rate of 267 patients, median age 40, was 82%. Twenty-eight percent of patients proceeded to alloHSCT in first CR. Age older than 55 years or a pre-HSCT event were the most common reasons for failure to progress to alloHSCT. At 5 years, overall survival (OS) was 44% after sib alloHSCT, 36% after MUD alloHSCT, and 19% after chemotherapy. After adjustment for sex, age, and white blood count and excluding chemotherapy-treated patients who relapsed or died before the median time to alloHSCT, only relapse-free survival remained significantly superior in the alloHSCT group (odds ratio 0.31, 95% confidence interval 0.16-0.61). An intention-to-treat analysis, using the availability or not of a matched sibling donor, showed 5-year OS to be nonsignificantly better at 34% with a donor versus 25% with no donor. This prospective trial in adult Ph+ ALL indicates a modest but significant benefit to alloHSCT. This trial has been registered with clinicaltrials.gov under identifier NCT00002514 and as ISRCTN77346223.
Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders
Magaña, Setty M. , Matiello, Marcelo , Pittock, Sean J. , McKeon, Andrew , Lennon, Vanda A. , Shuster, Elizabeth A., Kantarci, Orhun H. , Lucchinetti, Claudia F. , Weinshenker, Brian G. , Rabinstein, Alejandro A. , Pittock, S J , Weinshenker, Brian G , McKeon, Andrew

Mayo Clinic

Neurology | February 23, 2009 | Volume: 72 | Issue: 8 | Pages: 712-717

10.1212/01.wnl.0000343001.36493.ae | PMID 19237699 Get It

Follicular Lymphoma in the United States: First Report of the National LymphoCare Study
Friedberg, Jonathan W. , Cerhan, James R. , Flowers, Christopher R. , Dillon, Hildy, Rogers, Eric S., Hainsworth, John D. , Wong, Elaine K., Zelenetz, Andrew D. , Link, Brian K. , Taylor, Michael D. , Farber, Charles Michael , Vose, Julie M. , Cerhan, James R , Link, Brian K , Zelenetz, Andrew D

Mayo Clinic

Journal of Clinical Oncology | February 9, 2009 | Volume: 27 | Issue: 8 | Pages: 1202-1208

10.1200/jco.2008.18.1495 | PMID 19204203 Get It

Purpose Optimal therapy of follicular lymphoma (FL) is not defined. We analyzed a large prospective cohort study to identify current demographics and patterns of care of FL in the United States. Patients and Methods The National LymphoCare Study is a multicenter, longitudinal, observational study designed to collect information on treatment regimens and outcomes for patients with newly diagnosed FL in the United States. Patients were enrolled between 2004 and 2007. There is no study-specific prescribed treatment regimen or intervention. Results Two thousand seven hundred twenty-eight subjects were enrolled at 265 sites, including the 80% of patients enrolled from nonacademic sites. Using the Follicular Lymphoma International Prognostic Index (FLIPI), three distinct groups independent of histologic grade could be defined. Initial therapeutic strategy was: observation, 17.7%; rituximab monotherapy, 13.9%; clinical trial 6.1%; radiation therapy, 5.6%; chemotherapy only, 3.2%; chemotherapy plus rituximab, 51.9%. Chemotherapy plus rituximab regimens were: rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone, 55.0%; rituximab plus cyclophosphamide, vincristine, and prednisone, 23.1%; rituximab plus fludarabine based, 15.5%; other, 6.4%. The choice to initiate therapy rather than observe was associated with age, FLIPI, stage, and grade (P < .01). Significant differences in treatment (P < .01) across regions of the United States were noted. Contrary to practice guidelines, treatment of stage I FL frequently omits radiation therapy. Conclusion Widely disparate therapeutic approaches are utilized for FL. Initial therapy is deferred in a small subset of patients. There is no single standard of care for the treatment of de novo FL, although antibody use is ubiquitous when therapy is initiated. These disparate approaches to the initial care of patients with FL render a heterogeneous group of patients at relapse.
Neural Stem Cell– and Schwann Cell–Loaded Biodegradable Polymer Scaffolds Support Axonal Regeneration in the Transected Spinal Cord
Olson, Heather E. , Rooney, Gemma E., Gross, LouAnn, Nesbitt, Jarred J., Galvin, Katherine E., Chen, BingKun, Yaszemski, Michael J. , Windebank, Anthony J. , Knight, Andrew Michael

Mayo Clinic

Tissue Engineering Part A | February 3, 2009 | Volume: 15 | Issue: 7 | Pages: 1797-1805

10.1089/ten.tea.2008.0364 | PMID 19191513 Get It

Analytic and Clinical Utility of a Next-Generation, Highly Sensitive Cardiac Troponin I Assay for Early Detection of Myocardial Injury
Kavsak, Peter A. , MacRae, Andrew R., Yerna, Marie-Jeanne, Jaffe, Allan S. , Jaffe, Allan S. , Kavsak, Peter

Mayo Clinic

Clinical Chemistry | January 23, 2009 | Volume: 55 | Issue: 3 | Pages: 573-577

10.1373/clinchem.2008.116020 | PMID 19168557 Get It

Abstract Background: Improvements in cardiac troponin (cTn) assays have increased the rapidity with which clinicians can identify patients with changing cTn concentrations (rise or fall) indicative of acute myocardial injury. The aim of the present study was to characterize a new, high-sensitivity cTnI (hs-cTnI) assay and examine whether increased sensitivity can result in still earlier detection of evolving injury. Methods: We determined the limit of detection, precision profiles, and preliminary estimates of the 99th percentile for the Beckman Coulter hs-cTnI assay in 125 healthy individuals (age &lt;55 years, 54% male). We compared AccuTnI® and hs-cTnI to assess whether change criteria for early concentration changes (i.e., ≥3SD for low concentrations and 20% difference for concentrations &gt;0.10 μg/L) were exceeded in the first 2 specimens (median time between specimens, 1 h; 25th–75th percentile, 1–3 h) from subjects with symptoms suggestive of cardiac ischemia (n = 290). Results: The limit of detection for the hs-cTnI assay was 2.06 ng/L, and the 20% CV and 10% CV concentrations were 2.95 and 8.66 ng/L, respectively. The preliminary 99th percentile estimates in lithium heparin, serum, and EDTA plasma were 9.20, 8.00, and 8.60 ng/L, respectively. In 108 patients with myocardial injury based on the peak AccuTnI concentration, applying the change criteria on the 2 earliest specimens identified 81% (95% CI 73%–88%) of patients using the hs-cTnI assay compared to 62% (53%–71%) using the AccuTnI assay (P &lt; 0.001). Conclusions: Although more extensive validation studies are required, this Beckman Coulter hs-cTnI assay appears to detect patients with evolving myocardial injury earlier.
Case Report: Percutaneous Catheter Management of Persistent Urine Leak due to Iatrogenic Infundibular Stenosis after Partial Nephrectomy
Bruner, Bryan, Ashley, Richard , Leibovich, Bradley C. , Blute, Michael L., LeRoy, Andrew J.

Mayo Clinic

Journal of Endourology | January 2, 2009 | Volume: 23 | Issue: 1 | Pages: 37-42

10.1089/end.2008.0291 | PMID 19118467 Get It

A Synthesis of the World Literature of Ice Hockey Injuries: Epidemiologic Principles and Future Directions
Dajani, K. A., Crawford, B, Gill, Martin , Link, Andrew A., Smith, Aynsley M., Stuart, Michael J.

Mayo Clinic

Journal of ASTM International | December 30, 2008 | Volume: 5 | Issue: 10 | Pages: 1-45

10.1520/jai101778 Get It

Abstract Ice hockey is a fast-paced, aggressive sport whose participants are subject to relatively high rates of injury. Although there is a growing emphasis on the epidemiology of ice hockey research and its application towards reducing injuries, the literature has never been organized into an accessible database. Ice hockey is played in North America, Europe, Scandinavia, the U.K., and several other non-English speaking countries, yet injury reports not written in English are often ignored in review articles. The purpose of this project was to synthesize the existing world literature on ice hockey injuries into a framework of epidemiologic criteria, accessible in an organized, retrievable library. An extensive search of the following databases was done: MEDLINE, BIOSIS, EMBASE, NTIS, CURRENT CONTENTS, DISSERTATION ABSTRACTS, SPORT DISCUS, CINAHL, and WEB OF SCIENCE. Key words used were “ice hockey” and “injuries,” and the search range was 1966 to July 2007. Endnote X (Thompson Corp., Stamford, CT) was used for reference compilation. Eight hundred sixty seven documents were catalogued, from 27 countries in 8 languages. Documents were first categorized by type, including injury (226), equipment (45), case reports (94), review articles (294), editorials (39), or as focusing on the physiological, psychological, or medical aspects of ice hockey (169). Documents were then subdivided by study type and whether they were prospective (117) or retrospective (109). Further subdivisions beyond these levels were based on the inclusion of certain critical epidemiological criteria, including exposure time, a clear definition of “injury,” and the level of play, among others. This comprehensive database should make future ice hockey research more efficient, as well as promote sound epidemiology and a more global perspective.